RxDoctor Payments Data

Nicole Padron

Family · Easton, PANPI 1033580915

Payments from drug & device makers

$5,706in general payments, 2019–2025

Across 58 payments — averaging $98.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$5K
  • Janssen Products, LP$250
  • Viiv Healthcare Company$138
  • Janssen Scientific Affairs, LLC$109
  • Dexcom, Inc.$50
  • Lilly USA, LLC$29
  • plus $28 from 1 others

What the payments were for

  • Consulting fees$2,82049%
  • Travel & lodging$77714%
  • Food & beverage$2,06936%
  • Education$401%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,706 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,810
Medicare patients
14
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala248$940,010
TivicayDolutegravir Sodium125$258,342
DescovyEmtricitabine/Tenofov Alafenam82$165,935
PrezcobixDarunavir/Cobicistat56$129,147
OdefseyEmtricitab/Rilpiviri/Tenof Ala32$114,747
DovatoDolutegravir Sodium/Lamivudine28$77,324
GenvoyaElviteg/Cob/Emtri/Tenof Alafen19$71,953
PifeltroDoravirine21$35,095
MounjaroTirzepatide24$24,010
EliquisApixaban30$20,950
TrulicityDulaglutide14$11,774
XareltoRivaroxaban12$5,877
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,758
Atomoxetine Hcl12$2,159
Mometasone Furoate19$1,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$5,103$1,177,898349 claims
Viiv Healthcare CompanyTivicay, Dovato$138$335,665153 claims
Johnson & JohnsonPrezcobix, Xarelto$28$135,02568 claims
Lilly USA, LLCMounjaro, Trulicity$29$35,78438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Easton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →